Jeong Uk Lim1, Seung Wook Hong2, Jae-Hoon Ko3. 1. Department of Internal Medicine, Armed Forces Capital Hospital, Seongnam, Republic of Korea, Department of Internal Medicine, The Catholic University of Korea, Seoul, Republic of Korea. 2. Department of Internal Medicine, Armed Forces Capital Hospital, Seongnam, Republic of Korea, Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea. 3. Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06531, Republic of Korea.
Abstract
BACKGROUND: The efficacy of inhaled ciprofloxacin agents in the treatment of patients with bronchiectasis is controversial. The objective of the study was to review systematically the efficacy of inhaled ciprofloxacin agents in patients with bronchiectasis. METHODS: We searched PubMed, EMBASE, and Cochrane Library databases for randomized controlled trials (RCTs) evaluating inhaled ciprofloxacin agents among patients with bronchiectasis. Data were pooled using a meta-analysis technique. RESULTS: Two phase II and four phase III RCTs were included with a total of 1685 patients. Treatment durations of phase III studies were 48 weeks, while those of phase II studies were shorter. Pooled analysis of overall studies exhibited a statistically significant benefit of inhaled ciprofloxacin agents in three exacerbation outcome measures, including time to first exacerbation (hazard ratio 0.74, 95% confidence interval [CI] 0.63-0.86, I2 23%), exacerbation frequency (risk ratio [RR] 0.73, 95% CI 0.61-0.86, I2 42%), and exacerbation proportion (RR 0.85, 95% CI 0.76-0.96, I2 25%) without significant heterogeneity. Outcomes evaluating pulmonary function, quality of life, and adverse events were not significantly different between the two groups. Although eradication of respiratory pathogens was more frequently observed, the emergence of ciprofloxacin resistance was also significantly higher in the ciprofloxacin group. CONCLUSIONS: A meta-analysis of RCTs of inhaled ciprofloxacin agents showed clinical benefit in terms of pulmonary exacerbations in patients with bronchiectasis. Since a significant increase of resistance was also noticed, clinical trials with a longer study period are required for a conclusive assessment. The reviews of this paper are available via the supplemental material section.
BACKGROUND: The efficacy of inhaled ciprofloxacin agents in the treatment of patients with bronchiectasis is controversial. The objective of the study was to review systematically the efficacy of inhaled ciprofloxacin agents in patients with bronchiectasis. METHODS: We searched PubMed, EMBASE, and Cochrane Library databases for randomized controlled trials (RCTs) evaluating inhaled ciprofloxacin agents among patients with bronchiectasis. Data were pooled using a meta-analysis technique. RESULTS: Two phase II and four phase III RCTs were included with a total of 1685 patients. Treatment durations of phase III studies were 48 weeks, while those of phase II studies were shorter. Pooled analysis of overall studies exhibited a statistically significant benefit of inhaled ciprofloxacin agents in three exacerbation outcome measures, including time to first exacerbation (hazard ratio 0.74, 95% confidence interval [CI] 0.63-0.86, I2 23%), exacerbation frequency (risk ratio [RR] 0.73, 95% CI 0.61-0.86, I2 42%), and exacerbation proportion (RR 0.85, 95% CI 0.76-0.96, I2 25%) without significant heterogeneity. Outcomes evaluating pulmonary function, quality of life, and adverse events were not significantly different between the two groups. Although eradication of respiratory pathogens was more frequently observed, the emergence of ciprofloxacin resistance was also significantly higher in the ciprofloxacin group. CONCLUSIONS: A meta-analysis of RCTs of inhaled ciprofloxacin agents showed clinical benefit in terms of pulmonary exacerbations in patients with bronchiectasis. Since a significant increase of resistance was also noticed, clinical trials with a longer study period are required for a conclusive assessment. The reviews of this paper are available via the supplemental material section.
Authors: J Angrill; C Agustí; R de Celis; A Rañó; J Gonzalez; T Solé; A Xaubet; R Rodriguez-Roisin; A Torres Journal: Thorax Date: 2002-01 Impact factor: 9.139
Authors: Yuanyuan Wang; Tanja R Zijp; Muh Akbar Bahar; Janwillem W H Kocks; Bob Wilffert; Eelko Hak Journal: J Antimicrob Chemother Date: 2018-12-01 Impact factor: 5.790
Authors: The-Thien Tran; Hong Yu; Celine Vidaillac; Albert Y H Lim; John A Abisheganaden; Sanjay H Chotirmall; Kunn Hadinoto Journal: Int J Pharm Date: 2019-02-04 Impact factor: 5.875
Authors: Casilda Olveira; Gabriel Olveira; Inmaculada Gaspar; Antonio Dorado; Ivette Cruz; Federico Soriguer; Alexandra L Quittner; Francisco Espildora Journal: Qual Life Res Date: 2012-04-29 Impact factor: 4.147
Authors: Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne Journal: BMJ Date: 2011-10-18
Authors: James D Chalmers; Pieter Goeminne; Stefano Aliberti; Melissa J McDonnell; Sara Lonni; John Davidson; Lucy Poppelwell; Waleed Salih; Alberto Pesci; Lieven J Dupont; Thomas C Fardon; Anthony De Soyza; Adam T Hill Journal: Am J Respir Crit Care Med Date: 2014-03-01 Impact factor: 30.528
Authors: Anthony De Soyza; Timothy Aksamit; Tiemo-Joerg Bandel; Margarita Criollo; J Stuart Elborn; Elisabeth Operschall; Eva Polverino; Katrin Roth; Kevin L Winthrop; Robert Wilson Journal: Eur Respir J Date: 2018-01-25 Impact factor: 16.671
Authors: Eva Polverino; Pieter C Goeminne; Melissa J McDonnell; Stefano Aliberti; Sara E Marshall; Michael R Loebinger; Marlene Murris; Rafael Cantón; Antoni Torres; Katerina Dimakou; Anthony De Soyza; Adam T Hill; Charles S Haworth; Montserrat Vendrell; Felix C Ringshausen; Dragan Subotic; Robert Wilson; Jordi Vilaró; Bjorn Stallberg; Tobias Welte; Gernot Rohde; Francesco Blasi; Stuart Elborn; Marta Almagro; Alan Timothy; Thomas Ruddy; Thomy Tonia; David Rigau; James D Chalmers Journal: Eur Respir J Date: 2017-09-09 Impact factor: 16.671
Authors: Charles S Haworth; Juliet E Foweraker; Peter Wilkinson; Robert F Kenyon; Diana Bilton Journal: Am J Respir Crit Care Med Date: 2014-04-15 Impact factor: 21.405
Authors: Marta Garcia-Clemente; David de la Rosa; Luis Máiz; Rosa Girón; Marina Blanco; Casilda Olveira; Rafael Canton; Miguel Angel Martinez-García Journal: J Clin Med Date: 2020-11-24 Impact factor: 4.241